DOCSLIB.ORG

Draft Detailed Review Paper State of the Science on Novel in Vitro and in Vivo Screening and Testing Methods and Endpoints for Evaluating Endocrine Disruptors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Draft Detailed Review Paper State of the Science on Novel in Vitro and in Vivo Screening and Testing Methods and Endpoints for Evaluating Endocrine Disruptors Draft Detailed Review Paper State of the Science on Novel In Vitro and In Vivo Screening and Testing Methods and Endpoints for Evaluating Endocrine Disruptors Contractor: RTI International 3040 Cornwallis Road P.O. Box 12194 Research Triangle Park, NC 27709 Draft #2 November 2011 Authors Gerald A. LeBlanc, Ph.D. Seth W. Kullman, Ph.D. Department of Environmental and Department of Environmental and Molecular Toxicology Molecular Toxicology North Carolina State University North Carolina State University Raleigh, NC Raleigh, NC David O. Norris, Ph.D. William S. Baldwin, Ph.D. Department of Integrative Physiology Department of Biological Sciences and University of Colorado Environmental Toxicology Boulder, CO Clemson University Clemson, SC Werner Kloas, Ph.D. Department of Ecophysiology and John M. Greally, Ph.D. Aquaculture IGB Department of Genetics Endocrinology at Humboldt University Albert Einstein College of Medicine Germany Bronx, NY Screening and Testing Methods and Endpoints for Evaluating Endocrine Disruptors Table of Contents Abstract ..................................................................................................................................................... A-1 1. Introduction ......................................................................................................................................... 1-1 1.1 Relevance of this DRP to Diseases and Syndromes of Contemporary Concern ....................... 1-4 2. The Hypothalamic:Pituitary:Adrenocortical (HPA) Axis ................................................................... 2-1 2.1 Overview ................................................................................................................................... 2-1 2.1.1 Corticotropin-releasing Hormone (CRH) ................................................................... 2-2 2.1.2 Arginine Vasopressin (AVP)/Arginine Vasotocin (AVT) .......................................... 2-3 2.1.3 Corticotropin (ACTH) ................................................................................................ 2-3 2.1.4 Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG) ................................. 2-3 2.1.5 Glucocorticoids ........................................................................................................... 2-3 2.1.5.1 Glucocorticoid Receptors (GRs) .................................................................. 2-4 2.1.5.2 CRH and Glucocorticoid-Binding Protein (transcortinprotein and glucocorticoid-binding protein [transcortin]) ............................................... 2-4 2.1.6. Neuroendocrine Regulation of the HPA Axis ............................................................. 2-4 2.2 Consequences of Disruption ...................................................................................................... 2-5 2.3 Precedent Chemicals as Potential Disruptors of the HPA Axis ................................................. 2-5 2.3.1 Steroid Synthesis and Receptor Agonists and Antagonists......................................... 2-5 2.3.2 Metals .......................................................................................................................... 2-6 2.3.3 Neuroactive Chemicals ............................................................................................... 2-6 2.3.4 Vasopressin Receptor Agonists and Antagonists ........................................................ 2-6 2.3.5 CRH Receptor Antagonists ......................................................................................... 2-6 2.3.6 Pesticides .................................................................................................................... 2-7 2.3.7 Arylhydrocarbon Receptor (AhR) Agonists ............................................................... 2-7 2.3.8 Estrogens and Androgens ........................................................................................... 2-7 2.4 In Vitro Assays .......................................................................................................................... 2-7 2.4.1 Transactivation Reporter Assays ................................................................................ 2-7 2.4.2 Microarrays ................................................................................................................. 2-7 2.4.3 Cell Culture Systems ................................................................................................... 2-8 2.4.3.1 Corticotropes ................................................................................................ 2-8 2.4.3.2 Adrenal Cortical Cells .................................................................................. 2-8 2.4.3.3 Glucocorticoid Target Cells ......................................................................... 2-8 2.5 In Vivo Assays ........................................................................................................................... 2-8 2.5.1 Mammals .................................................................................................................... 2-9 2.5.2 Fish .............................................................................................................................. 2-9 2.5.2 Amphibians ................................................................................................................. 2-9 2.6 Strengths, Challenges, and Limitations ..................................................................................... 2-9 2.6.1 Stress, the Adverse Outcome Pathway, and Assay Selection ................................... 2-10 3. Hypothalamus:Pituitary:Gonad (HPG) Axis ....................................................................................... 3-1 3.1 Overview ................................................................................................................................... 3-1 3.1.1 Structure of the HPG Axis .......................................................................................... 3-1 3.1.2. Structure and Actions of HPG hormones .................................................................... 3-1 3.1.3. Function of the HPG Axis ........................................................................................... 3-3 3.2 Consequences of Disruption ...................................................................................................... 3-3 3.2.1 (Anti)estrogens ............................................................................................................ 3-3 3.2.1.1 Reproduction ................................................................................................ 3-4 3.2.1.2 Metabolism and Growth ............................................................................... 3-4 3.2.1.3 Immune System ............................................................................................ 3-5 ii Screening and Testing Methods and Endpoints for Evaluating Endocrine Disruptors 3.2.2 (Anti)androgens .......................................................................................................... 3-5 3.2.2.1 Reproduction ................................................................................................ 3-5 3.2.2.2 Growth .......................................................................................................... 3-6 3.2.3 (Anti)gestagens ........................................................................................................... 3-6 3.2.3.1 Reproduction ................................................................................................ 3-6 3.2.3.2 Immune System ............................................................................................ 3-7 3.3 Precedent Chemicals .................................................................................................................. 3-7 3.3.1 (Anti)estrogens ............................................................................................................ 3-7 3.3.1.1 Bisphenol A (BPA) ...................................................................................... 3-7 3.3.1.2 Phthalate Esters ............................................................................................ 3-8 3.3.1.3 Polychlorinated Biphenyls (PCBs) ............................................................... 3-8 3.3.2 (Anti)androgens .......................................................................................................... 3-9 3.3.2.1 Di-(2-ethylhexyl)phthalate (DEHP) ............................................................. 3-9 3.3.2.2 Flutamide ...................................................................................................... 3-9 3.3.3 (Anti)gestagens ........................................................................................................... 3-9 3.3.3.1 Levonorgestrel (LNG) .................................................................................. 3-9 3.4 In Vitro Assays .......................................................................................................................... 3-9 3.4.1 (Anti)estrogens .......................................................................................................... 3-10 3.4.1.1 ER Transactivation Assays ......................................................................... 3-10 3.4.1.2 Membrane Receptor Binding ..................................................................... 3-10 3.4.1.3 Cell-based Microarrays .............................................................................
Load more

Recommended publications
  • Types of Acute Phase Reactants and Their Importance in Vaccination (Review)
    BIOMEDICAL REPORTS 12: 143-152, 2020 Types of acute phase reactants and their importance in vaccination (Review) RAFAAT H. KHALIL1 and NABIL AL-HUMADI2 1Department of Biology, College of Science and Technology, Florida Agricultural and Mechanical University, Tallahassee, FL 32307; 2Office of Vaccines, Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD 20993, USA Received May 10, 2019; Accepted November 25, 2019 DOI: 10.3892/br.2020.1276 Abstract. Vaccines are considered to be one of the most human and veterinary medicine. Proteins which are expressed cost-effective life-saving interventions in human history. in the acute phase are potential biomarkers for the diagnosis The body's inflammatory response to vaccines has both of inflammatory disease, for example, acute phase proteins desired effects (immune response), undesired effects [(acute (APPs) are indicators of successful organ transplantation phase reactions (APRs)] and trade‑offs. Trade‑offs are and can be used to predict the ameliorative effect of cancer more potent immune responses which may be potentially therapy (1,2). APPs are primarily synthesized in hepatocytes. difficult to separate from potent acute phase reactions. The acute phase response is a spontaneous reaction triggered Thus, studying acute phase proteins (APPs) during vaccina- by disrupted homeostasis resulting from environmental distur- tion may aid our understanding of APRs and homeostatic bances (3). Acute phase reactions (APRs) usually stabilize changes which can result from inflammatory responses. quickly, after recovering from a disruption to homeostasis Depending on the severity of the response in humans, these within a few days to weeks; however, APPs expression levels reactions can be classified as major, moderate or minor.
    [Show full text]
  • Ptvg-HP Vaccine Protocol
    Version 10/7/2015 Randomized Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) versus GM-CSF Adjuvant in Patients with Non-Metastatic Prostate Cancer CO 08801 Investigational Agent: BB IND 12109 - pTVG-HP DNA encoding human prostatic acid phosphatase Study Sponsors: 56 patients – treated at UWCCC and UCSF Department of Defense Prostate Cancer Research Program federal grant 50 patients in biomarker cohort – treated at UWCCC, UCSF and JHU Madison Vaccines Inc. (MVI) corporate sponsor STUDY SITE INFORMATION Study Sites: University of Wisconsin Carbone Cancer Center (UWCCC) 1111 Highland Avenue Madison, WI 53705 University of California San Francisco (UCSF) Johns Hopkins School of Medicine (JHU) Study Principal Investigator: Douglas G. McNeel, M.D., Ph.D. UWCCC 7007 Wisconsin Institutes for Medical Research 1111 Highland Ave. Madison, WI 53705 Tel: (608) 263-4198 Fax: (608) 265-0614 [email protected] UWCCC Local Principal Investigator : Glenn Liu, MD UWCCC 7051 Wisconsin Institutes for Medical Research 1111 Highland Ave. Madison, WI 53705 Tel : (608) 265-8689 Fax : (608) 265-5146 [email protected] Medical Monitor: Mark Albertini, M.D. UWCCC 600 Highland Ave. K6/5 CSC Madison, WI 53792 Tel: (608) 265-8131 Fax: (608) 265-8133 [email protected] Other UWCCC Investigators: Joshua Lang, M.D. – Clinical Investigator Christos Kyriakopolous, M.D. – Clinical Investigator Robert Jeraj, Ph.D. – Medical Physics, Quantitative Total Bone Imaging Scott Perlman, M.D. – Nuclear Medicine UCSF Principal Investigator: Lawrence Fong, M.D. JHU Principal Investigator: Emmanuel Antonarakis, MD Study Coordinator: Mary Jane Staab, R.N. B.S.N. UWCCC 600 Highland Ave.
    [Show full text]
  • Supplementary Information Changes in the Plasma Proteome At
    Supplementary Information Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease Julia Muenchhoff1, Anne Poljak1,2,3, Anbupalam Thalamuthu1, Veer B. Gupta4,5, Pratishtha Chatterjee4,5,6, Mark Raftery2, Colin L. Masters7, John C. Morris8,9,10, Randall J. Bateman8,9, Anne M. Fagan8,9, Ralph N. Martins4,5,6, Perminder S. Sachdev1,11,* Supplementary Figure S1. Ratios of proteins differentially abundant in asymptomatic carriers of PSEN1 and APP Dutch mutations. Mean ratios and standard deviations of plasma proteins from asymptomatic PSEN1 mutation carriers (PSEN1) and APP Dutch mutation carriers (APP) relative to reference masterpool as quantified by iTRAQ. Ratios that significantly differed are marked with asterisks (* p < 0.05; ** p < 0.01). C4A, complement C4-A; AZGP1, zinc-α-2-glycoprotein; HPX, hemopexin; PGLYPR2, N-acetylmuramoyl-L-alanine amidase isoform 2; α2AP, α-2-antiplasmin; APOL1, apolipoprotein L1; C1 inhibitor, plasma protease C1 inhibitor; ITIH2, inter-α-trypsin inhibitor heavy chain H2. 2 A) ADAD)CSF) ADAD)plasma) B) ADAD)CSF) ADAD)plasma) (Ringman)et)al)2015)) (current)study)) (Ringman)et)al)2015)) (current)study)) ATRN↓,%%AHSG↑% 32028% 49% %%%%%%%%HC2↑,%%ApoM↓% 24367% 31% 10083%% %%%%TBG↑,%%LUM↑% 24256% ApoC1↓↑% 16565% %%AMBP↑% 11738%%% SERPINA3↓↑% 24373% C6↓↑% ITIH2% 10574%% %%%%%%%CPN2↓%% ↓↑% %%%%%TTR↑% 11977% 10970% %SERPINF2↓↑% CFH↓% C5↑% CP↓↑% 16566% 11412%% 10127%% %%ITIH4↓↑% SerpinG1↓% 11967% %%ORM1↓↑% SerpinC1↓% 10612% %%%A1BG↑%%% %%%%FN1↓% 11461% %%%%ITIH1↑% C3↓↑% 11027% 19325% 10395%% %%%%%%HPR↓↑% HRG↓% %%% 13814%% 10338%% %%% %ApoA1 % %%%%%%%%%GSN↑% ↓↑ %%%%%%%%%%%%ApoD↓% 11385% C4BPA↓↑% 18976%% %%%%%%%%%%%%%%%%%ApoJ↓↑% 23266%%%% %%%%%%%%%%%%%%%%%%%%%%ApoA2↓↑% %%%%%%%%%%%%%%%%%%%%%%%%%%%%A2M↓↑% IGHM↑,%%GC↓↑,%%ApoB↓↑% 13769% % FGA↓↑,%%FGB↓↑,%%FGG↓↑% AFM↓↑,%%CFB↓↑,%% 19143%% ApoH↓↑,%%C4BPA↓↑% ApoA4↓↑%%% LOAD/MCI)plasma) LOAD/MCI)plasma) LOAD/MCI)plasma) LOAD/MCI)plasma) (Song)et)al)2014)) (Muenchhoff)et)al)2015)) (Song)et)al)2014)) (Muenchhoff)et)al)2015)) Supplementary Figure S2.
    [Show full text]
  • (1982), 24(4), 329—337 Pineal Response to Lithium1
    Indian J. Psychiat. (1982), 24(4), 329—337 PINEAL RESPONSE TO LITHIUM1 S. PARVATHI DEVI* A. VENKOBA RAO> PINEAL FUNCTION AND BEHAVIOUR—A until Crowther demonstrated from his REVIEW autopsy studies that pineal calcification The pineal gland in ma.i is an active had nothing to do with mental derange­ endocrine gland throughout life (Wurtman ment. et al., 1964 ; Tapp & Huxley, 1972 ; Interest in the pineal gland lay dormant Cardinali, 1974 ; Reiter et al., 1975 ; Reiter, and the gland was relegated to be a ves- 1978). It elaborates several hormones with tigeal organ until the endocrine nature precise rhythmicity. The chronobiological of the gland was suggested following des­ aspects of the mammalian pineal gland have criptions of pineal tumours associated with been clearly brought out by Reiler (198!) precocious puberty (Kitay, 1954). The defining the circadian rhythms in indole idea of a special relation of pineal gland to metabolism within the pineal of mammals. mind was revived in reports of experiments The two major classes of pineal hormones— with pineal extracts in the treatment of pineal indoles (melatonin, serotonin and schizophrenia (Becker, 1920 ; Eldered et the tryptophols) and the polypeptides are al., 196U; Kitay & Altschule, 1954). The known to influence several physiological isolation and characterisation of the pineal systems including the central nervous system hormone melatonin was a turning point (Cardinali, 1974 and Anton Tay, 1974). in pineal research (Lerner et al., 1958). The association of pineal gland with be­ Since then the pineal gland has been a haviour and mental illness can be traced to focus of intense scientific enquiry revealing Alexandrian school of thought (Herophilus it to be an endocrine gland capable of c.
    [Show full text]
  • R Graphics Output
    Dexamethasone sodium phosphate ( 0.339 ) Melengestrol acetate ( 0.282 ) 17beta−Trenbolone ( 0.252 ) 17alpha−Estradiol ( 0.24 ) 17alpha−Hydroxyprogesterone ( 0.238 ) Triamcinolone ( 0.233 ) Zearalenone ( 0.216 ) CP−634384 ( 0.21 ) 17alpha−Ethinylestradiol ( 0.203 ) Raloxifene hydrochloride ( 0.203 ) Volinanserin ( 0.2 ) Tiratricol ( 0.197 ) trans−Retinoic acid ( 0.192 ) Chlorpromazine hydrochloride ( 0.191 ) PharmaGSID_47315 ( 0.185 ) Apigenin ( 0.183 ) Diethylstilbestrol ( 0.178 ) 4−Dodecylphenol ( 0.161 ) 2,2',6,6'−Tetrachlorobisphenol A ( 0.156 ) o,p'−DDD ( 0.155 ) Progesterone ( 0.152 ) 4−Hydroxytamoxifen ( 0.151 ) SSR150106 ( 0.149 ) Equilin ( 0.3 ) 3,5,3'−Triiodothyronine ( 0.256 ) 17−Methyltestosterone ( 0.242 ) 17beta−Estradiol ( 0.24 ) 5alpha−Dihydrotestosterone ( 0.235 ) Mifepristone ( 0.218 ) Norethindrone ( 0.214 ) Spironolactone ( 0.204 ) Farglitazar ( 0.203 ) Testosterone propionate ( 0.202 ) meso−Hexestrol ( 0.199 ) Mestranol ( 0.196 ) Estriol ( 0.191 ) 2,2',4,4'−Tetrahydroxybenzophenone ( 0.185 ) 3,3,5,5−Tetraiodothyroacetic acid ( 0.183 ) Norgestrel ( 0.181 ) Cyproterone acetate ( 0.164 ) GSK232420A ( 0.161 ) N−Dodecanoyl−N−methylglycine ( 0.155 ) Pentachloroanisole ( 0.154 ) HPTE ( 0.151 ) Biochanin A ( 0.15 ) Dehydroepiandrosterone ( 0.149 ) PharmaCode_333941 ( 0.148 ) Prednisone ( 0.146 ) Nordihydroguaiaretic acid ( 0.145 ) p,p'−DDD ( 0.144 ) Diphenhydramine hydrochloride ( 0.142 ) Forskolin ( 0.141 ) Perfluorooctanoic acid ( 0.14 ) Oleyl sarcosine ( 0.139 ) Cyclohexylphenylketone ( 0.138 ) Pirinixic acid ( 0.137 )
    [Show full text]
  • Chlorinated and Polycyclic Aromatic Hydrocarbons in Riverine and Estuarine Sediments from Pearl River Delta, China
    Environmental Pollution 117 (2002) 457–474 www.elsevier.com/locate/envpol Chlorinated and polycyclic aromatic hydrocarbons in riverine and estuarine sediments from Pearl River Delta, China Bi-Xian Maia,*, Jia-Mo Fua, Guo-Ying Shenga, Yue-Hui Kanga, Zheng Lina, Gan Zhanga, Yu-Shuan Mina, Eddy Y. Zengb aState Key Lab Laboratory of Organic Geochemistry, Guangzhou Institute of Geochemistry, Chinese Academy of Sciences, PO Box 1130, Guangzhou, Guangdong 510640, People’s Republic of China bSouthern California Coastal Water Research Project, 7171 Fenwick Lane, Westminster, CA 92683, USA Received 5 January 2001; accepted 3 July 2001 ‘‘Capsule’’: Sediments of the Zhujiang River and Macao Harbor have the potential to be detrimental to biological systems. Abstract Spatial distribution of chlorinated hydrocarbons [chlorinated pesticides (CPs) and polychlorinated biphenyls (PCBs)] and poly- cyclic aromatic hydrocarbons (PAHs) was measured in riverine and estuarine sediment samples from Pearl River Delta, China, collected in 1997. Concentrations of CPs of the riverine sediment samples range from 12 to 158 ng/g, dry weight, while those of PCBs range from 11 to 486 ng/g. The CPs concentrations of the estuarine sediment samples are in the range 6–1658 ng/g, while concentrations of PCBs are in the range 10–339 ng/g. Total PAH concentration ranges from 1168 to 21,329 ng/g in the riverine sediment samples, whereas the PAH concentration ranges from 323 to 14,812ng/g in the sediment samples of the Estuary. Sediment samples of the Zhujiang River and Macao harbor around the Estuary show the highest concentrations of CPs, PCBs, and PAHs. Possible factors affecting the distribution patterns are also discussed based on the usage history of the chemicals, hydrologic con- dition, and land erosion due to urbanization processes.
    [Show full text]
  • Pharmacological Management of Acromegaly: a Current Perspective
    Neurosurg Focus 29 (4):E14, 2010 Pharmacological management of acromegaly: a current perspective SUNIL MANJILA , M.D.,1 Osmo N D C. WU, B.A.,1 FAH D R. KHAN , M.D., M.S.E.,1 ME H ree N M. KHAN , M.D.,2 BAHA M. AR A F AH , M.D.,2 AN D WA rre N R. SE L M AN , M.D.1 1Department of Neurological Surgery, The Neurological Institute, and 2Division of Clinical and Molecular Endocrinology, University Hospitals Case Medical Center, Cleveland, Ohio Acromegaly is a chronic disorder of enhanced growth hormone (GH) secretion and elevated insulin-like growth factor–I (IGF-I) levels, the most frequent cause of which is a pituitary adenoma. Persistently elevated GH and IGF-I levels lead to substantial morbidity and mortality. Treatment goals include complete removal of the tumor causing the disease, symptomatic relief, reduction of multisystem complications, and control of local mass effect. While trans- sphenoidal tumor resection is considered first-line treatment of patients in whom a surgical cure can be expected, pharmacological therapy is playing an increased role in the armamentarium against acromegaly in patients unsuitable for or refusing surgery, after failure of surgical treatment (inadequate resection, cavernous sinus invasion, or transcap- sular intraarachnoid invasion), or in select cases as primary treatment. Three broad drug classes are available for the treatment of acromegaly: somatostatin analogs, dopamine agonists, and GH receptor antagonists. Somatostatin analogs are considered as the first-line pharmacological treatment of acromegaly, although effica- cy varies among the different formulations. Octreotide long-acting release (LAR) appears to be more efficacious than lanreotide sustained release (SR).
    [Show full text]
  • Cross Discipline Team Leader Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 203255Orig1s000 CROSS DISCIPLINE TEAM LEADER REVIEW Cross Discipline Team Leader Review pituitary adenoma (pituitary acromegaly) and only very rarely to an ectopic source of GH. Therefore for practical purposes, acromegaly is a pituitary disease. Although the treatment of choice of pituitary acromegaly is surgical removal of the pituitary mass via transsfenoidal route, the success rate is variable (90% in patients with microadenoma and below 50% in patients with macroadenomas). Patients who fail surgery (or cannot undergo surgery for a variety of reasons) benefit from radiation or pharmacological therapy. Because the effects of radiation may take years to reach effectiveness, medical therapy is almost invariably used in patients who respond poorly or incompletely to surgical management. Tight GH control and a normalization of serum IGF-1 are the goals of medical treatment. GH reductions to ≤1 μg/L using a modern sensitive immunoassay (approximately equivalent to 2.5 μg/L measured by RAI)2 following an oral glucose load are desirable. There are three drug products that have been approved by the FDA for the medical treatment of acromegaly. From a mechanism of action perspective they belong to two distinct classes: somatostatin analogs (octreotide and lanreotide) and GH receptor antagonists (pegvisomant). Pegvisomant (SOMAVERT) is a pegylated GH analog and acts as a GH receptor antagonist. It competes with endogenous GH for GH receptor binding. Once bound to the GH receptor it prevents receptor dimerization and subsequent intracellular signaling, thus blocking generation of IGF-1. The major safety signal identified with pegvisomant is transient liver enzyme elevation; however, no drug-induced liver failure has been documented to date.
    [Show full text]
  • Dibenzofuran, 4-Chromanone, Acetophenone, and Dithiecine Derivatives: Cytotoxic Constituents from Eupatorium Fortunei
    International Journal of Molecular Sciences Article Dibenzofuran, 4-Chromanone, Acetophenone, and Dithiecine Derivatives: Cytotoxic Constituents from Eupatorium fortunei Chun-Hao Chang 1, Semon Wu 2, Kai-Cheng Hsu 3,4, Wei-Jan Huang 5,6 and Jih-Jung Chen 7,8,9,* 1 Institute of Biopharmaceutical Sciences, School of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei 112, Taiwan; [email protected] 2 Department of Life Science, Chinese Culture University, Taipei 110, Taiwan; [email protected] 3 Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan; [email protected] 4 Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan 5 Ph.D. Program in Biotechnology Research and Development, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan; [email protected] 6 Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan 7 Department of Pharmacy, School of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei 112, Taiwan 8 Faculty of Pharmacy, National Yang-Ming University, Taipei 112, Taiwan 9 Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 404, Taiwan * Correspondence: [email protected]; Tel.: +886-2-2826-7195; Fax: +886-2-2823-2940 Abstract: Five new compounds, eupatodibenzofuran A (1), eupatodibenzofuran B (2), 6-acetyl-8- methoxy-2,2-dimethylchroman-4-one (3), eupatofortunone (4), and eupatodithiecine (5), have been isolated from the aerial part of Eupatorium fortunei, together with 11 known compounds (6-16).
    [Show full text]
  • A Guide to Transthyretin Amyloidosis
    A Guide to Transthyretin Amyloidosis Authored by Teresa Coelho, Bo-Goran Ericzon, Rodney Falk, Donna Grogan, Shu-ichi Ikeda, Mathew Maurer, Violaine Plante-Bordeneuve, Ole Suhr, Pedro Trigo 2016 Edition Edited by Merrill Benson, Mathew Maurer What is amyloidosis? Amyloidosis is a systemic disorder characterized by extra cellular deposition of a protein-derived material, known as amyloid, in multiple organs. Amyloidosis occurs when native or mutant poly- peptides misfold and aggregate as fibrils. The amyloid deposits cause local damage to the cells around which they are deposited leading to a variety of clinical symptoms. There are at least 23 different proteins associated with the amyloidoses. The most well-known type of amyloidosis is associated with a hematological disorder, in which amyloid fibrils are derived from monoclonal immunoglobulin light-chains (AL amyloidosis). This is associated with a clonal plasma cell disorder, closely related to and not uncommonly co-existing with multiple myeloma. Chronic inflammatory conditions such as rheumatoid arthritis or chronic infections such as bronchiectasis are associated with chronically elevated levels of the inflammatory protein, serum amyloid A, which may misfold and cause AA amyloidosis. The hereditary forms of amyloidosis are autosomal dominant diseases characterized by deposition of variant proteins, in dis- tinctive tissues. The most common hereditary form is transthyretin amyloidosis (ATTR) caused by the misfolding of protein monomers derived from the tetrameric protein transthyretin (TTR). Mutations in the gene for TTR frequently re- sult in instability of TTR and subsequent fibril formation. Closely related is wild-type TTR in which the native TTR protein, particu- larly in the elderly, can destabilize and re-aggregate causing non- familial cases of TTR amyloidosis.
    [Show full text]
  • To Download a List of Prescription Drugs Requiring Prior Authorization
    Essential Health Benefits Standard Specialty PA and QL List July 2016 The following products require prior authorization. In addition, there may be quantity limits for these drugs, which is notated below. Therapeutic Category Drug Name Quantity Limit Anti-infectives Antiretrovirals, HIV SELZENTRY (maraviroc) None Cardiology Antilipemic JUXTAPID (lomitapide) 1 tab/day PRALUENT (alirocumab) 2 syringes/28 days REPATHA (evolocumab) 3 syringes/28 days Pulmonary Arterial Hypertension ADCIRCA (tadalafil) 2 tabs/day ADEMPAS (riociguat) 3 tabs/day FLOLAN (epoprostenol) None LETAIRIS (ambrisentan) 1 tab/day OPSUMIT (macitentan) 1 tab/day ORENITRAM (treprostinil diolamine) None REMODULIN (treprostinil) None REVATIO (sildenafil) Soln None REVATIO (sildenafil) Tabs 3 tabs/day TRACLEER (bosentan) 2 tabs/day TYVASO (treprostinil) 1 ampule/day UPTRAVI (selexipag) 2 tabs/day UPTRAVI (selexipag) Pack 2 packs/year VELETRI (epoprostenol) None VENTAVIS (iloprost) 9 ampules/day Central Nervous System Anticonvulsants SABRIL (vigabatrin) pack None Depressant XYREM (sodium oxybate) 3 bottles (540 mL)/30 days Neurotoxins BOTOX (onabotulinumtoxinA) None DYSPORT (abobotulinumtoxinA) None MYOBLOC (rimabotulinumtoxinB) None XEOMIN (incobotulinumtoxinA) None Parkinson's APOKYN (apomorphine) 20 cartridges/30 days Sleep Disorder HETLIOZ (tasimelteon) 1 cap/day Dermatology Alkylating Agents VALCHLOR (mechlorethamine) Gel None Electrolyte & Renal Agents Diuretics KEVEYIS (dichlorphenamide) 4 tabs/day Endocrinology & Metabolism Gonadotropins ELIGARD (leuprolide) 22.5 mg
    [Show full text]
  • Pharmacology – Inhalant Anesthetics
    Pharmacology- Inhalant Anesthetics Lyon Lee DVM PhD DACVA Introduction • Maintenance of general anesthesia is primarily carried out using inhalation anesthetics, although intravenous anesthetics may be used for short procedures. • Inhalation anesthetics provide quicker changes of anesthetic depth than injectable anesthetics, and reversal of central nervous depression is more readily achieved, explaining for its popularity in prolonged anesthesia (less risk of overdosing, less accumulation and quicker recovery) (see table 1) Table 1. Comparison of inhalant and injectable anesthetics Inhalant Technique Injectable Technique Expensive Equipment Cheap (needles, syringes) Patent Airway and high O2 Not necessarily Better control of anesthetic depth Once given, suffer the consequences Ease of elimination (ventilation) Only through metabolism & Excretion Pollution No • Commonly administered inhalant anesthetics include volatile liquids such as isoflurane, halothane, sevoflurane and desflurane, and inorganic gas, nitrous oxide (N2O). Except N2O, these volatile anesthetics are chemically ‘halogenated hydrocarbons’ and all are closely related. • Physical characteristics of volatile anesthetics govern their clinical effects and practicality associated with their use. Table 2. Physical characteristics of some volatile anesthetic agents. (MAC is for man) Name partition coefficient. boiling point MAC % blood /gas oil/gas (deg=C) Nitrous oxide 0.47 1.4 -89 105 Cyclopropane 0.55 11.5 -34 9.2 Halothane 2.4 220 50.2 0.75 Methoxyflurane 11.0 950 104.7 0.2 Enflurane 1.9 98 56.5 1.68 Isoflurane 1.4 97 48.5 1.15 Sevoflurane 0.6 53 58.5 2.5 Desflurane 0.42 18.7 25 5.72 Diethyl ether 12 65 34.6 1.92 Chloroform 8 400 61.2 0.77 Trichloroethylene 9 714 86.7 0.23 • The volatile anesthetics are administered as vapors after their evaporization in devices known as vaporizers.
    [Show full text]